Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that generics erosion, particularly for best-selling beta blockers and angiotensin-converting enzyme inhibitors, will result in slow market growth for the treatment of chronic heart failure.

Medical News Today (http://www.medicalnewstoday.com/medicalnews.php?newsid=37007#)